Hemostatik Ajan Olarak Kullanılan Mecsina Hemostopper©, Ankaferd Blood Stopper® ve Traneksamik Asidin İmmunolojik Farklılıklarının Hücre Kültürü Çalışması ile Araştırılması

Amaç:Tıp ve diş hekimliğinin birçok uygulamasında, tedavi sırasında veya sonrasında görülen beklenmedik kanamalar, yapılan işlemin büyüklüğünden bağımsız olarak gelişebilecek bir komplikasyon olarak değerlendirilir. Kanamanın kontrol altına alınmasını kolaylaştırmak amacıyla cerrahi işlem öncesinde ve/veya sonrasında kullanılabilecek birçok biyomalzeme üretilmiştir. Bu çalışmada kanama durdurucu ajan olarak kullanılan Ankaferd Blood Stopper® (ABS), Traneksamik Asit (TA) ve yeni bir kanama durdurucu olan Mecsina Hemostopper®’ın(MH) immünolojik etkinlikleri ve etkilerinin karşılaştırılması amaçlanmıştır. Yöntem: Çalışmada pıhtılaşma ve fibrin oluşumu üzerinde en çok çalışma yapılan ölümsüz hücre içeriğine sahip insan umblikal kord hücreleri (HUVEC, Human Umbilical Vein Endothelial Cell ) kullanılmıştır. Her flaska her bir ilaç için 5000 hücre olacak şekilde 5 gruba (ABS grubu, TA grubu, MH grubu, distile su uygulanan negatif grup ve herhangi bir uygulama yapılmayan kontrol grubu) hücreler dağıtıldı. Bulgular: Elde edilen verilere göre 1:2 ve 1:10’ luk konsantrasyonlarda; MH uygulaması yapılan hücrelerde Tümör Nekrozis Faktör Alfa (TNF-α) seviyeleri diğer ilaç gruplarına göre daha düşüktür (p

Investigation of Immunological Differences in Mecsina Hemostopper©, Ankaferd Blood Stopper® and Tranexamic Acid Used as Haemostatic Agents with Cell Culture Study

Objective: Hemorrhagic complications may develop in many branches ofmedicine and dentistry after or during the treatment independently of the ex tent of the procedure performed. Various biomaterialshave been used in the medical and dental practiceprocedures before and after surgical procedures. Theaim of this study was to compare the immunologicalefficacies and effects of Ankaferd Blood Stopper®(ABS), Tranexamic acid (TA) used as anti-hemorrhagicagents and Mecsina Hemostopper©(MH), a newanti-hemorrhagic agent. Method: The immortalizedHuman Umbilical Vein Endothelial Cell (HUVEC) celllines, which are human umbilical cord cells and usedin many studies on coagulation and formation of fibrin,were commercially purchased for the study. The cells,5000 cells per flask for each drug, were distributedinto the 5 groups (ABS Group, TA group, MH group,distilled water-administered negative group and controlwithout any administration). Results: Accordingto the data we obtained, Tumor Necrosis Factor Alpha(TNF-α) levels were found to be lower in the cells, towhich MH was administered at concentrations of 1:2 and 1:10, than other drug groups (p

PDF

___

Amanvermez R, Gunay M, Piskin A, Keles G, Tomak L. TNF-α, IL-1β, and oxidative stress during fracfracture healing with or without ankaferd. Bratisl Lek Listy. 2013; 114(11): 621-4.
Lange J, Sapozhnikova A, Lu C, Hu D, Li X, Miclau T et al. Action of IL-1β during fracture healing. J Orthop Res. 2010; 28(6): 778-84.
Jones KL, De Kretser DM, Patella S, Phillips DJ. Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol. 2004; 225(1-2): 119-25.
Later AF, Sitniakowsky LS, Van Hilten JA, Van De Watering L, Brand A, Smit NP, et al. Antifibrinolytics attenuate inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg. 2013; 145(6): 1611-6.
Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg. 2010; 110(2): 350-3.
Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs. 2002; 62(5): 2193-211.
Bilgili H, Captug O, Kosar A, Kurt M, Kekilli M, Shorgabi A, et al. Oral systemic administration of Ankaferd Blood Stopper has no short-term toxicity in an in vivo rabbit experimental model. Clin Appl Thromb Hemost. 2010; 16(5): 533-6.
Yılmaz E, Gülec ŞS, Torun D, Haznedaroglu IC, Akar N. The effects of Ankaferd® Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile. Turk J Hematol. 2011; 28(4): 276-85.
Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007; 11(6): R117.
Cole E, Davenport R, Willett K, Brohi K. Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Ann Surg. 2015; 261(2): 390-4.
Balvers K, Van Dieren S, Baksaas-Aasen K, Gaarder C, Brohi K, Eaglestone S, et al. Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. Br J Surg. 2017; 104(3): 222-9
Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, McClelland B, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007; 17(4): CD001886.
Nuttall GA, Gutierrez MC, Dewey JD, Johnson ME, Oyen LJ, Hanson AC, et al. A preliminary study of anew tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth. 2008; 22(2): 230-5.
Emes Y, Aybar B, Vural P, Issever H, Yalcın S, Atalay B, et al. Effects of hemostatic agents on fibroblast cells. Implant Dent. 2014; 23(6): 641-7.
Goker H, Haznedaroglu IC, Ercetin S, Kirazli S, Akman U, Ozturk Y, et al. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd Blood Stopper. J Int Med Res. 2008; 36(1): 163–70.
Lee SJ, Umano K, Shibamoto T, Lee KG. Identification of volatile components in basil (Ocimum basilicum L.) and thyme leaves (Thymus vulgaris L.) and their antioxidant properties. Food Chem. 2007; 91(1): 131-7.
Simsek HO, Tuzum MS, Baykul T, Gurer IE, Bassorgun CI. Experimental investigation of the effects of a blood stopper agent (ankaferd blood stopper) on bone surfaces. Turk J Hematol. 2013; 30(2): 177-83